Tango Therapeutics (TNGX) Research & Development (2020 - 2026)

Tango Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $33.5 million for Q1 2026.

• In Q1 2026, Research & Development fell 7.98% year-over-year to $33.5 million; the TTM figure through Mar 2026 stood at $129.3 million (down 9.16% YoY), while the FY2025 annual figure was $132.2 million, down 8.17% from the prior year.
• Research & Development was $33.5 million for Q1 2026 at Tango Therapeutics, up from $32.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $38.7 million in Q2 2024 to a low of $23.7 million in Q2 2022.
• Historically, Research & Development has averaged $31.2 million across 5 years, with a median of $31.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Research & Development surged 62.2% in 2022, then declined 15.13% in 2025.
• A 5-year view of Research & Development shows it stood at $29.1 million in 2022, then advanced by 7.73% to $31.3 million in 2023, then gained by 8.29% to $33.9 million in 2024, then declined by 5.41% to $32.1 million in 2025, then advanced by 4.46% to $33.5 million in 2026.
• The last three Research & Development figures came in at $33.5 million (Q1 2026), $32.1 million (Q4 2025), and $30.8 million (Q3 2025), per Business Quant data.